Humacyte: Saving lives with lab-grown blood vessels in conflict zones

Trauma surgeons in Ukraine operating theaters saved lives and limbs thanks to the innovative lab-grown blood vessels from US biotech, Humacyte.Humacyte is pioneering a platform that enables the investigation, development, and manufacture of bioengineered human tissues and organs that are designed to be universally implantable, off-the-shelf, and regenerative, with the goal of treating a wide variety of diseases, injuries, and chronic conditions.This week I had the chance to speak to Humacyte founder, President and Chief Executive Laura Niklason about the company she has built, the science she is driving forward, and the real-world applications for Humacyte’s lab-grown blood vessels in some of the most devastating and dangerous conflicts.1:00     Introducing Laura Niklason4:50     Humacyte and its mission6:27     Competitive landscape7:45     Partnering for scale9:49     How to grow blood vessels in the lab11:47   Implanting the vessels13:32   Human vessels vs synthetic vessels15:10   The manufacturing process16:23   Overcoming skepticism, demonstrating value19:01   Navigating the regulatory approval process21:17   The role of the Department of Defense in innovative biotech22:30   Using Humacyte vessels in the field23:20   Humacyte vessels in the Ukraine War28:22   Lessons from the Ukraine War30:09   Goals for the coming years33:35   Scaling manufacturingInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic:Current trends & innovations in 3D organoidsThe future of organ transplants: Xenotransplantation, 3D bioprinting and stem cells